

Test Specific Guidelines

DermTech Pigmented Lesion Assay

MOL.TS.282.A**v1.0.2023**

Procedures Addressed

The inclusion of any procedure code in this table is provided for informational purposes and is not a guarantee of coverage nor an indication that prior authorization is required.

<u>Procedures addressed by this guideline</u>	<u>Procedure code</u>
<u>DermTech Pigmented Lesion Assay</u>	<u>0089U</u>

What Is Melanoma?

Definition

According to the American Academy of Dermatology (AAD), the incidence of primary cutaneous melanoma has been increasing substantially for several decades. The incidence of melanoma has been reported to be increasing at a rate of 3% to 7% annually among fair-skinned Caucasian populations, which is faster than other major cancers.¹

Melanoma accounts for the majority of skin cancer related deaths, but treatment is nearly always curative with early detection of disease. Minimal depth (thin) melanomas have a cure rate of nearly 100%, while tumors with a Breslow depth of greater than 4mm have a 10-year survival rate of less than 50%.¹

Standard of care for the assessment of clinically suspicious pigmented skin lesions is surgical biopsy with pathologic evaluation. However, histopathology is believed to have inherent limitations. Some lesions that are likely to be true melanomas based on clinical behavior do not meet the complete set of histologic criteria to establish a melanoma diagnosis.¹ There is also considerable interrater variability with visual image and pattern recognition of skin lesions.² In an effort to improve patient survival, a number of novel noninvasive techniques have been developed to classify pigmented skin lesions at an earlier stage.³

Test Information

Introduction

The Pigmented Lesion Assay (PLA) is a non-invasive method for the biopsy of clinically atypical pigmented lesions or moles using an adhesive patch to obtain mRNA from the surface of the suspicious lesion.

According to the manufacturer, the PLA assesses gene expression consistent with melanoma and is intended as a decision making aid for the clinician to determine whether or not to biopsy a pigmented skin lesion, clinically suspicious for melanoma.⁴ The test is intended for use on pigmented lesions suspicious for melanoma that meet at least one of the A (asymmetry) B (border) C (color) D (diameter) E (evolving) criteria for which the clinician would like additional information prior to surgical biopsy. Uses of the PLA include the following: lesions being followed for change; lesions in cosmetically sensitive areas of the body; lesions on patients with possible risks for complications during surgical biopsy; or lesions among patients who refuse biopsy.⁴

The PLA is a non-invasive method for the biopsy of clinically atypical pigmented lesions or moles using an adhesive patch to obtain mRNA from the surface of the suspicious lesion. The method of adhesive tape stripping has been used to obtain RNA from the stratum corneum for gene expression of other disorders, such as allergic and irritant skin reactions and psoriasis.⁵ The PLA detects the expression of 2 specific genes, PRAME and LINC00518, both of which are believed to play key roles in oncogenesis and both of which have been shown to be elevated in melanoma. If one or more of the genes is detected by the PLA, the gene expressive is considered positive. The positive lesions generally undergo surgical biopsy to definitively establish a melanoma diagnosis.⁴ The test manufacturer notes that this assay cannot be used on mucous membranes, palms of the hands, or soles of the feet.²

Guidelines and Evidence

Introduction

The following section includes relevant guidelines and evidence pertaining to DermTech PLA.

American Academy of Dermatology

The American Academy of Dermatology (AAD) acknowledges that the clinical and prognostic significance of the use of biomarkers and mutational analysis is still unclear and there are gaps regarding their clinical usefulness that have yet to be addressed.³ The 2019 guideline stated:

“Ancillary diagnostic molecular techniques (eg, CGH, FISH, GEP) may be used for equivocal melanocytic neoplasms.”

“Routine molecular testing, including GEP [gene expression profiling], for prognostication is discouraged until better use criteria are defined. The application of molecular information for clinical management (eg, sentinel lymph node eligibility, follow-up, and/or therapeutic choice) is not recommended outside of a clinical study or trial.”

“Once a lesion has been identified as clinically concerning, dermoscopy can improve diagnostic accuracy and/or help direct optimal and adequate tissue sampling in the case of very large lesions or those in cosmetically or functionally sensitive areas. Newer noninvasive techniques (eg, reflectance confocal microscopy [RCM], as well as electrical impedance spectroscopy, gene expression analysis, optical coherence tomography, and others can also be considered as these become more readily available.”

“Lingering questions remain regarding the degree to which the selected gene sets represent genes associated with tumor progression, how they compare with current well-characterized prognostic factors and AJCC eighth edition survival data, and whether they improve prognostic models enough to affect patient management and outcomes. As such, the WG discourages routine baseline GEP for prognostication.”

“There is insufficient evidence to recommend routine molecular profiling assessment for baseline prognostication. Evidence is lacking that molecular classification should be used to alter patient management outside of current guidelines (eg, NCCN and AAD). The criteria for and the utility of prognostic molecular testing, including GEP, in aiding clinical decision making (eg, SLNB eligibility, surveillance intensity, and/or therapeutic choice) needs to be evaluated in the context of clinical study or trial.”

“Noninvasive genomic methods (eg, adhesive patch “biopsy”) are being investigated to further classify melanocytic lesions as either benign or malignant to guide the need for further biopsy. The uptake of 1 or more of these technologies will eventually depend on cumulative evidence regarding their effectiveness, clinical utility, cost versus benefit, and competing strategies.”

National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN, 2022) makes no recommendation to consider or use the DermTech PLA test in the evaluation of skin lesions suspicious for melanoma.⁶

With regard to GEP, NCCN offered the following guidance:⁶

“The use of gene expression profiling (GEP) testing according to specific AJCC-8 melanoma stage (before or after sentinel lymph node biopsy [SNLB]) requires further prospective investigation in large, contemporary data sets of unselected patients. Prognostic GEP testing to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures. Moreover, since there is a low probability of metastasis in stage I (T1) melanoma and a higher proportion of false-positive results, GEP testing should not guide clinical decision-making in this subgroup.”

“Pre-diagnostic clinical modalities (ie, total-body photography and sequential digital dermoscopy), and other imaging technologies (eg, reflectance confocal microscopy, electrical impedance spectroscopy) may enhance early detection of

new primary melanoma in patients with high mole count and/or presence of clinical atypical nevi. Pre-diagnostic noninvasive patch testing may also be helpful to guide biopsy decisions.”

With regard to diagnostic testing, NCCN stated:⁶

“Melanocytic neoplasms of uncertain biological potential present a unique challenge to pathologists and treating clinicians. Ancillary tests to differentiate benign from malignant melanocytic neoplasms include immunohistochemistry (IHC), and molecular testing via comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), gene expression profiling (GEP), single nucleotide polymorphism *SNP) array, and next-generation sequencing (NGS). These tests may facilitate a more definitive diagnosis and guide therapy in cases that are diagnostically uncertain or controversial by histopathology. Ancillary tests should be used as adjuncts to clinical and expert dermatopathologic examination and therefore be interpreted within the context of these findings.”

Selected Relevant Publications

There is insufficient evidence to support the use of DermTech PLA to accurately discriminate between early melanoma and non-melanoma in patients with clinically suspicious lesions.^{1,2,7-20} A recurring limitation within the evidence base is the assumption that non-biopsied PLA negative results are true negatives without follow up assessment for confirmation. Additional limitations include retrospective study designs, small individual study populations, overlapping patient populations, varying follow up times, and a lack of reported health outcomes.

Based on the current evidence, PLA testing may have a high negative predictive value and influence clinical management decisions regarding biopsy but it remains unclear if these PLA-based decisions result in clinically meaningful patient outcomes. Well-designed studies that report the impact of PLA testing on clinical management decisions together with the health outcomes that result from those decisions are needed to confirm the utility of the DermTech PLA test.

Criteria

Introduction

Requests for DermTech PLA are reviewed using the following criteria.

This test is considered investigational and/or experimental.

Investigational and experimental (I&E) molecular and genomic (MolGen) tests refer to assays involving chromosomes, DNA, RNA, or gene products that have insufficient data to determine the net health impact, which typically means there is insufficient data to support that a test accurately assesses the outcome of interest (analytical and clinical validity), significantly improves health outcomes

(clinical utility), and/or performs better than an existing standard of care medical management option. Such tests are also not generally accepted as standard of care in the evaluation or management of a particular condition.

In the case of MolGen testing, FDA clearance is not a reliable standard given the number of laboratory developed tests that currently fall outside of FDA oversight and FDA clearance often does not assess clinical utility.

References

Introduction

This guideline cites the following references

Gerami P, Alsobrook JP II, Palmer TJ, Robin HS. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin. *J Am Acad Dermatol*. 2014; 71:237-244.

Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. *J Am Acad Dermatol*. 2017; 76(1):114-120.

Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. 2019 Jan;80(1) : 208-250.

Pigmented Lesion Assay (PLA). DermTech website. Available at: <http://dermtech.com/products/pla/>.

Wachsman W, Morhenn V, Palmer T, et al. Noninvasive genomic detection of melanoma. *Br J Dermatol*. 2011; 164:797-806.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. Cutaneous Melanoma. Version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

Ferris LK, Jansen B, Ho J, et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. *JAMA Dermatol*. 2017; 153(7):675-680.

Ferris LK, Moy RL, Gerami P, et al. Noninvasive analysis of high-risk driver mutations and gene expression profiles in primary cutaneous melanoma. *J Invest Dermatol*. 2019 May;139(5):1127-1134.

Ferris LK, Gerami P, Skelsey MK, et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. *Melanoma Research*. 2018;28(5):478-482.

Ferris LK, Rigel DS, Siegel DM, et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test

results and utility data from a large US registry study. *Dermatol Online J.* 2019;25(5):2.

Yao Z, Allen T, Oakley M, et al. Analytical characteristics of a noninvasive gene expression assay for pigmented skin lesions. *Assay Drug Dev Technol.* 2016;14(6):355-363. doi: 10.1089/adt.2016.724

Yao Z, Moy R, Allen T, et al. An adhesive patch-based skin biopsy device for molecular diagnostics and skin microbiome studies. *J Drugs Dermatol.* 2017;16(10):979-986.

Brouha B, Ferris LK, Skelsey MK, et al. Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: A large US registry study. *J Drugs Dermatol.* 2020;19(3):257-262. doi: 10.36849/JDD.2020.4766

Beatson M, Weinstock MA. Further consideration of the pigmented lesion assay. *JAMA Dermatology.* 2019;155(3):393-393. doi: 10.1001/jamadermatol.2018.5478

Rivers J, Copley M, Svoboda R, et al. Non-invasive gene expression testing to rule out melanoma. *Skin Therapy Lett.* 2018;23(5):1-4. doi: 10.1001/jamadermatol.2018.1764.

Shah A, Hyngstrom J, Florell SR, et al. Use of the pigmented lesion assay to rapidly screen a patient with numerous clinically atypical pigmented lesions. *JAAD Case Reports.* 2019;5(12):1048-1050. doi: 10.1016/j.jdc.2019.10.004

Robinson JK, Jansen B. Caring for melanoma survivors with self-detected concerning moles during COVID-19 restricted physician access: a cohort study. *SKIN The Journal of Cutaneous Medicine.* 2020;4(3):248. doi: 10.25251/skin.4.3.5

Jackson SR, Jansen B, Yao Z, et al. Risk stratification of severely dysplastic nevi by non-invasively obtained gene expression and mutation analyses. *SKIN The Journal of Cutaneous Medicine.* 2020;4(2):124-129. doi: 10.36849/JDD.2020.4766.

Brouha B, Ferris L, Skelsey M, et al. Genomic atypia to enrich melanoma positivity in biopsied lesions: Gene expression and pathology findings from a large U.S. registry study. *SKIN The Journal of Cutaneous Medicine.* 2021;5(1):13–18. doi.org/10.25251/skin.5.1.3

Skelsey M, Brouha B, Rock J, et al. Non-invasive detection of genomic atypia increases real-world NPV and PPV of the melanoma diagnostic pathway and reduces biopsy burden. *SKIN.* 2021;5(5):512-523. doi: 10.25251/skin.5.5.9. Feb 1996;33(2):168-70.